Regulus Therapeutics Inc (NASDAQ:RGLS) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $1.83 and last traded at $1.90, with a volume of 426 shares trading hands. The stock had previously closed at $1.92.
A number of equities research analysts recently issued reports on RGLS shares. Leerink Swann lowered Regulus Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 10th. Wedbush reaffirmed a “hold” rating and issued a $1.00 target price on shares of Regulus Therapeutics in a research note on Friday, August 10th. B. Riley reduced their target price on Regulus Therapeutics from $1.00 to $0.50 and set a “neutral” rating on the stock in a research note on Friday, July 6th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Saturday, October 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Friday, August 10th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $1.42.
The company has a market cap of $17.46 million, a PE ratio of -0.17 and a beta of 1.37.
A hedge fund recently bought a new stake in Regulus Therapeutics stock. A.R.T. Advisors LLC purchased a new position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned 0.16% of Regulus Therapeutics as of its most recent SEC filing.
About Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.